GlassScriptPhysician profile
Sungjun J Hwang
NPI 1255334132
$1,673.34
in general payments reported to CMS, 2019-2025
21 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $70.76 · 2022: $119 · 2023: $506 · 2024: $327 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.15 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $294.63 | 2022-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Bausch & Lomb Americas INC. | $233.45 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Regeneron Healthcare Solutions, INC. | $210.67 | 2019-2024 | Eylea, Eylea Hd |
| Rxsight INC | $184.79 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| New World Medical,INC. | $137.90 | 2022-2023 | |
| Carl Zeiss Meditec USA, INC. | $93.60 | 2024-2025 | |
| Abbvie INC. | $82.93 | 2024-2025 | |
| Amgen INC. | $73.93 | 2024-2025 | Tepezza |
| Beaver-Visitec International, INC. | $55.44 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $44.26 | 2025 | Yutiq |
| Novartis Pharmaceuticals Corporation | $36.82 | 2019-2023 | |
| Carl Zeiss Meditec Cataract Technology INC. | $34.38 | 2024 | |
| Glaukos Corporation | $29.97 | 2020-2024 | Idose |
| Ivantis, INC | $24.90 | 2020 | |
| Ocular Therapeutix, INC. | $23.68 | 2025 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $23.56 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.17 | 2019 | |
| Spark Therapeutics, INC. | $20.52 | 2019 | |
| Shire North American Group INC | $16.52 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.28 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.94 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sungjun Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.